Biodel Inc. (NASDAQ: BIOD), is expected to present data results from studies of Linjeta (previously known as VIAject) this week between 9/20/2010 to 09/23/2010 at the 46^th annual meeting of the European Association for the Study of Diabetes in Stockholm.

Linjeta™, which is currently under review by FDA for a marketing approval with a PDUFA date (FDA approval decision date) of October 30, 2010, is a proprietary more-rapid-acting injectable regular human insulin under development for meal-time use by people with Type 1 or Type 2 diabetes to improve glycemic control. 

On July 1, 2010, Biodel Inc. (Nasdaq: BIOD) announced that the following abstracts describing results from studies related to the company's product candidates have been accepted for presentation in September during the 46th annual meeting of the European Association for the Study of Diabetes in Stockholm. 

Oral Presentation:

 #OP 01, Oral session on novel formulations and delivery of insulin, Tuesday, September 21, 2010 10:45 AM - 12:15 PM "A novel pH-neutral formulation of the monomeric insulin VIAject(R) has a faster onset of action than insulin lispro"; to be presented by Dr. T. Heise, Profil Institut fur Stoffwechselforschung GmbH, Neuss, Germany

Poster Presentations: 

#PS 089 Poster session on short-acting insulins, Thursday, September 23, 2010 12:30 PM - 1:30 PM "Biocompatibility of the ultra-rapid insulin VIAject(R) with continuous insulin infusion sets"; to be presented by Dr. F. Flacke, Biodel, Inc. 

#PS 089 Poster session on short-acting insulins, Thursday, September 23, 2010 12:30 PM - 1:30 PM "Pharmacokinetics of novel formulations of insulin analogs that provide a more rapid onset of action in diabetic miniature swine"; to be presented by Dr. R. Pohl, Biodel, Inc.

The abstracts can be accessed through the association's website, www.easd.org.

Source: http://investor.biodel.com/releasedetail.cfm?ReleaseID=484547

Subscribe to future developments and other latest news updates: